High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationRapid COJEC versus standard induction therapies for high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaPlatinum-induced hearing loss after treatment for childhood cancerNeuroblastoma: issues in transplantationOverview and recent advances in the treatment of neuroblastoma.Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastomaOxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.Optimization of liposomal topotecan for use in treating neuroblastoma.Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupComparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma.Acetaminophen induces human neuroblastoma cell death through NFKB activation.Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Local control in metastatic neuroblastoma in children over 1 year of ageNeuroblastoma: developmental biology, cancer genomics and immunotherapy.Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyTargeting focal adhesion kinase in neuroblastoma.Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.Advances in Risk Classification and Treatment Strategies for Neuroblastoma.Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionHigh genomic instability predicts survival in metastatic high-risk neuroblastoma.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.Morphological Differentiation Towards Neuronal Phenotype of SH-SY5Y Neuroblastoma Cells by Estradiol, Retinoic Acid and Cholesterol.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study.
P2860
Q24186451-E84DCE2E-D659-4DD1-9C42-D5C41C246AB8Q24187922-564F8892-4207-460C-A5F9-8FE60A502AD4Q24197871-B8135753-EF67-4AB4-B99A-F4F048528BC8Q24310296-89A78B6C-E332-4869-9E52-582C0AB01967Q26470526-65C7AF66-B0AE-4BA7-BCF7-1F8FE7FD2124Q27008197-A1AD1DE2-55FA-4FA1-BE32-57E70D4582BAQ30238693-34E927D5-872A-4B62-8471-1745985D37BEQ30730580-2FC6E213-1F7C-4738-AC62-312F96FF9C00Q33408675-95EEEF0B-D426-4F7C-9CDD-72B0C280F38CQ33419558-2652DB3C-B806-4F59-B8B2-3A34C44C744FQ33441292-B6385E49-21D2-4F0E-8B79-C5CFA33C72F3Q33618501-3D79F51A-96AC-4C7A-96C5-934D92820412Q33743767-4D37D29A-7A46-4A5A-8A6F-E3DE2BEA959BQ33775276-C579C1EC-D809-4B57-AA7B-3596B91852F3Q33999779-412E9F6C-F73C-4B79-9F52-04B631EA2C66Q34319964-052DB96F-BEBF-4753-8157-6EF293093CC8Q34483063-5F9D57CE-6588-4CD5-AA17-AE343FC5E2CEQ34541113-5BD26468-FD3C-4C2D-8539-955ED08BA07DQ34703990-F8348B58-3995-44D4-BD90-1A34C470B885Q35068556-68DE819E-59E8-410B-830F-2398D9BF7B4DQ35077703-98B6AFAF-D0A6-4BF3-BDF1-DA4854B91C21Q35146875-EEFD7109-FE47-4CE1-ABBE-8B458CC19F82Q35283020-63AE1009-D5D6-4358-9372-980E4647B934Q35565630-DA52A3BE-B068-4A47-A5A0-D1EB7422D81DQ35576162-A19501EB-9551-4778-B893-F030B238EA3CQ35760648-837450AC-BB91-4B72-A44A-B7F2D240A641Q35798960-9B3225F3-A850-4CBC-9ED9-D1DB83FA7AB4Q35818767-CA033850-ACAD-40A2-84F6-C1EFB67DA9EFQ36053801-94D4C48B-CF16-424E-92A1-FF276682EE82Q36057459-8736588C-8AC1-4B14-B76D-2E3D9C7083EEQ36212437-D5818FB8-0F9E-405C-8587-5EAEAD68A35FQ36282735-81A992CE-AC68-4C34-A224-3D6A08EC6984Q36294761-04729704-97A9-48C6-B7AA-BF2D4211B4FBQ36353230-39DF8552-E775-4F5D-9A81-FA9BA02B2725Q36739006-F6DDBFB8-EC0A-4592-A515-57F463A10A55Q36778207-B4938C45-EE6A-4D40-BD5C-877C5CE4F81DQ36782374-AAAADABB-2467-4575-99A3-496143E4F65CQ36914450-E4E863FB-2DB9-4878-8577-0231A00E6A98Q36962575-86AE3445-CBCC-4D30-90B8-5225F66A44C3Q37123462-478CF96E-C5CA-4AB7-A426-EB440BAA2A03
P2860
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@ast
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@en
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@nl
type
label
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@ast
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@en
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@nl
prefLabel
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@ast
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@en
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@nl
P2093
P1433
P1476
High-dose rapid and standard i ...... oblastoma: a randomised trial.
@en
P2093
Andrew D J Pearson
C Ross Pinkerton
Caroline Ellershaw
Children's Cancer and Leukaemi ...... Children's Cancer Study Group)
David Machin
European Neuroblastoma Study Group
Ian J Lewis
John Imeson
P304
P356
10.1016/S1470-2045(08)70069-X
P577
2008-03-01T00:00:00Z